Gene Solutions - Công ty cổ phần giải pháp Gene
Our Investments

Gene Solutions

Fund

Mekong Enterprise Fund IV

Deal Leader

Ashley Trang Pham

Website

 

Gene Solutions is a pioneering genetic testing service company in Asia dedicated to developing and providing access to Next-Generation Sequencing (NGS) testing. Also known as high-throughput sequencing, NGS is a powerful technology that allows scientists to rapidly sequence DNA or RNA much more efficiently and cost-effectively than traditional methods like Sanger sequencing.  

The company provides three main categories of innovative genetic testing products. 

Making genetic testing affordable and accessible for millions of Vietnamese

Reproductive Health

Non-Invasive Prenatal Testing (NIPT) is a highly accurate and safe screening method used during pregnancy to assess the risk of certain genetic conditions in a fetus. Conducted as early as 9-10 weeks into gestation, NIPT analyzes fragments of fetal DNA known as cell -free DNA (cfDNA) that circulate in the mother’s bloodstream.

To meet the diverse needs of customers, Gene Solutions has developed three distinct versions of NIPT test – triSure product lines including triSureFirst, triSureCarrier and triSureProcare:

triSureFirst

triSureFirst a screening test for the three most common chromosomal abnormalities in fetuses: Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). The test is performed from the 9th week of pregnancy onwards and is recommended as the first screening test for pregnant women.  

triSureCarrier a screening test for nine recessive genetic disorders among parents, helping assess the possibility of disease inheritance to their children. Can be performed before or during pregnancy.  

triSureProcare expands prenatal screening by analyzing 7,018 mutations linked to the 25 most prevalent single-gene disorders, which may significantly affect a child’s quality of life and require early intervention to avoid being missed during development. Additionally, it screens for 7,535 mutations associated with 18 recessive genetic conditions inherited from the mother, offering a broader and more personalized view of fetal health.  

Gene Solution is pioneering the expansion into early detection of diseases common the pregnant women, including gestational diabetes and pre-eclampsia, which effect 11.5% and 2,2% – 5.2% of pregnant women in Asia respectively.

triSureFirst a screening test for the three most common chromosomal abnormalities in fetuses: Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). The test is performed from the 9th week of pregnancy onwards and is recommended as the first screening test for pregnant women.  

triSureCarrier a screening test for nine recessive genetic disorders among parents, helping assess the possibility of disease inheritance to their children. Can be performed before or during pregnancy.  

triSureProcare expands prenatal screening by analyzing 7,018 mutations linked to the 25 most prevalent single-gene disorders, which may significantly affect a child’s quality of life and require early intervention to avoid being missed during development. Additionally, it screens for 7,535 mutations associated with 18 recessive genetic conditions inherited from the mother, offering a broader and more personalized view of fetal health.  

Gene Solution is pioneering the expansion into early detection of diseases common the pregnant women, including gestational diabetes and pre-eclampsia, which effect 11.5% and 2,2% – 5.2% of pregnant women in Asia respectively.

Early Cancer Detection  

With the outstanding advantage of the advanced machine learning system and large genetic data, Gene Solution has invented a Screening for Preclinical Origin and Tissue with Multimodal AI and Sequencing (SPOT-MAS™SPOT-MAS™) liquid biopsy technology to enhance the early-stage detection of many cancers as the next breakthrough pillar. 

With superior sensitivity in detecting rare circulating tumor DNA (ctDNA) and lower costs compared to market standards, SPOT-MAS™ offers an affordable Point-of-Care (POC) solution for cancer screening and management. This makes it especially impactful in developing countries, where 75% of global cancer deaths occur and access to traditional screening programs is limited.  

SPOT-MAS Multi Cancer Early Detection (MCED) is a cutting-edge liquid biopsy test that detects genomic abnormalities across multiple common cancers including liver, lung, breast, colorectal, and stomach using circulating tumor DNA (ctDNA) from a simple blood draw. It detects early cancer signals before symptoms appear and identifies both the presence and likely origin of multiple cancer types in asymptomatic individuals.  

Notably, SPOT-MAS has become the first multi-cancer screening blood test in Asia to successfully complete a large-scale prospective cohort validation, with results published in BMC Medicine, marking a major milestone in early cancer detection.  

Read more on clinical trials

In addition to multi-cancer early detection, Gene Solution also has single cancer early detection that may be recommended for people that are at risk to certain types of cancer  

SPOT-MAS Lung is a blood-based test designed for individuals at high risk of lung cancer, especially those aged 50–80 with a history of smoking, exposure to air pollution, or family history of lung disease. It is ideal for people who may not qualify for or have access to low-dose Computed Tomography (CT) scans due to concerns about radiation exposure and limited availability of CT devices, offering a safe, accurate, and non-invasive alternative for early detection. If you’re in a high-risk group, SPOT-MAS Lung could help catch cancer early when it’s most treatable.  

Read more on clinical trials

 

 

SPOT-MAS Colorectal (coming soon) is a blood-based test designed for individuals at high risk of colorectal cancer, such as those aged 40+, with a family history, poor diet, or chronic bowel conditions. It detects early cancer signals from ct-DNA using advanced sequencing and AI, offering a non-invasive alternative to colonoscopy. 

Clinical Oncology - Cancer Treatment and Remission

K-TRACK™ Genomic Profiling & ctDNA-MRD Monitoring is a next-generation sequencing assay that provides comprehensive insights into a patient’s genomic landscape. By analyzing a broad panel of genes, it identifies key mutations that guide personalized cancer treatment decisions. 

Once a patient’s unique genetic profile is established, K-TRACK™ enables precise tracking of Minimal Residual Disease (MRD)—the small number of cancer cells that may remain after treatment and are undetectable by standard imaging. Using circulating tumor DNA (ctDNA), K-TRACK™ offers high sensitivity and specificity, validated in peer-reviewed studies, and can detect cancer recurrence up to 19 months earlier than conventional methods. 

Introduced by Gene Solutions in 2023, K-TRACK™ empowers clinicians with real-time monitoring and early relapse prediction, supporting truly personalized oncology care. 

Read more on clinical trial

Nhà sáng lập công ty cổ phần giải pháp Gene (Gene Solutions)
Dr. Nguyen Hoai Nghia, Dr. Giang Hoa, and Dr. Nguyen Huu Nguyen.

Mission to make genetic testing affordable and accessible for millions of Vietnamese

After spending 10 years conducting advanced research in Cancer Biology and Genetics research in the United States, Dr. Nguyen Hoai Nghia was profoundly moved by the life-saving potential of genetic testing. But what struck him most was the realization that such advanced healthcare solutions were still out of reach for millions back home in Vietnam. Motivated by a deep sense of responsibility and a desire to give back, he returned to Vietnam with a mission: to make genetic testing affordable and accessible for every Vietnamese family — transforming lives through early cancer detection and personalized care. 

In 2017, Dr. Nghia together co-founded Gene Solutions with Dr. Nguyen Huu Nguyen, and Dr. Giang Hoa with background and solid experience in genetics, cancer biology, clinical medicine, and biotechnology. 

Strategic Partnership with Mekong Capital in 2021

The partnership between Mekong Capital and Gene Solutions began in October 2021, when Mekong Capital’s Mekong Enterprise Fund IV (MEF IV) invested $15 million to support Gene Solutions’ mission of making advanced genetic testing accessible across Vietnam and Southeast Asia. This strategic partnership was built on a shared vision of transforming healthcare through innovation, affordability, and scale.

Mekong Capital’s investment enabled Gene Solutions to accelerate its growth in reproductive health, expand into clinical oncology, and enhance its AI-powered genetic testing technologies. Since the investment, Gene Solutions has significantly scaled its operations, tripled its test volume, and expanded into over 10 Asian markets. 

Since Mekong Capital’s investment, this innovative competitive advantage combined with an elite team with rich industry experience and leadership has enabled Gene Solutions to emerge as the leading genetic testing firm offering comprehensive solutions in reproductive health and clinical oncology, including early cancer detection and cancer recurrence monitoring. 

By 2025, Gene Solutions is Asia’s DNA testing champion in both reproductive health and clinical oncology, recognized for its market dominance and remarkable achievements: 

  • Over 2.2 million AI-enhanced Next-generation sequencing (NGS) tests processed and tripled the annual test volume since MEF IV’s initial investment. 
  • 6 Next-generation sequencing (NGS) labs, including 2 College of American Pathologist (CAP) – accredited centers in Vietnam and Singapore. 2 (CAP) Accredited NGS Labs: A CAP-accredited lab meets rigorous standards for quality and accuracy in laboratory testing. This accreditation is internationally recognized and ensures that the lab follows best practices in clinical diagnostics, including next-generation sequencing. 
  • 50+ peer-reviewed publications, validating both scientific rigor and clinical relevance 

Revolution in cancer screening and detection and become Vietnam’s market-leading genetic testing business.

  • A growing presence in 10+ Asian markets, driven by partnerships with leading hospital chains in Vietnam, Philippines, Indonesia, Thailand, Singapore… 

By 2025, Gene Solutions proudly leads Vietnam’s reproductive health sector, commanding an impressive 85% market share and enabling thousands of expectant mothers to access affordable, high-quality genetic testing. In oncology, the company collaborates with 4,500+ hospitals and clinics with 2,500+ partner doctors, and to deliver comprehensive care from early cancer detection to recurrence monitoring. 

Key global partnership of Gene Solutions

F88

F88

Next Investment